Showing 1-4 of 4 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Repurposing antianginal drugs for immunomodulation in Type 1 Diabetes | Medical University of Vienna | Philipp Hohensinner | Cures | 01-April-2023 to 30-September-2025 | $288,927.00 |
| An open-label extension multi-centre trial in adult subjects diagnosed with Type 1 diabetes mellitus exploring the effect of long-term Verapamil SR therapy on the preservation of beta-cell function | Medical University of Graz | Thomas Pieber | Cures | 01-January-2025 to 31-December-2027 | $600,000.00 |
| Chemical ARX degraders | CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences | Stefan Kubicek | Cures | 01-June-2024 to 31-May-2026 | $199,853.60 |
| Targeting mannosylation for regenerating beta cell mass | CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences | Stefan Kubicek | Cures | 01-December-2022 to 30-November-2025 | $495,146.74 |